Abstract：【Objective】To investigate the correlation between the severity of chronic atrophic gastritis (CAG) and miR-32, miR-181 and miR-129.【Methods】A total of 130 CAG patients (observation group) admitted to the Shangluo Central Hospital from August 2019 to August 2021 were selected, and 130 healthy volunteers (control group) who underwent physical examination at the same time were selected. The expression levels of miR-32, miR-181 and miR-129 were compared between the two groups. The ROC curve was used to analyze the expression levels of miR-32, miR-181, and miR-129 to predict the value of CAG and the expression levels of miR-32, miR-181, and miR-129 in CAG patients with different disease severity were compared at the same time. Spearman coefficient was used to analyze the correlation between the expression level of miR-32, miR-181, miR-129 and the severity of the disease in CAG patients.【Results】The expression levels of miR-32 and miR-181 in the observation group were significantly higher than those in the control group, and the expression levels of miR-129 were significantly lower than those in the control group (P<0.05). ROC curve analysis showed that the best cutoff values of miR-32, miR-181 and miR-129 for CAG prediction were 3.150, 0.813 and 3.288, and the areas under the curve were 0.931, 0.880 and 0.904 respectively (P<0.05). The expression levels of miR-32 and miR-181 gradually increased in mild, moderate and severe patients, and the expression levels of miR-129 gradually decreased, with a statistically significant difference (P<0.05). Spearman correlation analysis showed that the expression level of miR-32 and miR-181 in CAG patients was positively correlated with the severity of the disease (P<0.05), and the expression level of miR-129 was negatively correlated with the severity of the disease (P<0.05). 【Conclusion】 The expression levels of serum miR-32, miR-181 and miR-129 are related to the severity of the disease in patients with CAG, and can be used as a relevant indicator to predict the severity of the disease in patients with CAG.
2022, Vol. 39 
